Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
暂无分享,去创建一个
A. Ashworth | A. Tutt | T. Crook | C. Lord | N. Syed | M. Gasco | O. Garrone | N. Turner | E. Iorns | R. Elliott | Elizabeth Iorns
[1] M. Dowsett,et al. Predictors of response to aromatase inhibitors , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[2] L. Nicholson,et al. Epigenetic Inactivation Implies Independent Functions for Insulin-like Growth Factor Binding Protein (IGFBP)-Related Protein 1 and the Related IGFBPL1 in Inhibiting Breast Cancer Phenotypes , 2007, Clinical Cancer Research.
[3] A. Ashworth,et al. Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.
[4] J. Brenton,et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. , 2007, Cancer cell.
[5] Michael Peyton,et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.
[6] J. Bergh,et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Nir Hacohen,et al. Minimizing the risk of reporting false positives in large-scale RNAi screens , 2006, Nature Methods.
[8] L. Lim,et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.
[9] Michael C. Ostrowski,et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis , 2005, Oncogene.
[10] R. Kumar,et al. Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment , 2005, The Journal of Steroid Biochemistry and Molecular Biology.
[11] E. McDermott,et al. Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.
[12] Maurice P H M Jansen,et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Schiff,et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.
[14] Stephen E. Jones. A New Estrogen Receptor Antagonist – An Overview of Available Data , 2002, Breast Cancer Research and Treatment.
[15] V. Jordan,et al. “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer , 2004, Breast Cancer Research and Treatment.
[16] M. Dowsett. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .
[17] E. Sausville,et al. Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.
[18] V. Laudet,et al. The nuclear receptor superfamily , 2003, Journal of Cell Science.
[19] O. Stål,et al. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.
[20] F. Kern,et al. Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells , 2001 .
[21] I. Ellis,et al. Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.
[22] Margaret Kasten,et al. Cdk10, a Cdc2-related kinase, associates with the Ets2 transcription factor and modulates its transactivation activity , 2001, Oncogene.
[23] F. Kern,et al. Hyperactivation of MAPK Induces Loss of ER a Expression in Breast Cancer Cells , 2001 .
[24] J. Slingerland,et al. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] R. Blamey,et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] D. Tripathy,et al. Tamoxifen for early breast cancer: An overview of the randomised trials , 1999 .
[27] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[28] S. Kharbanda,et al. Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis , 1997, Oncogene.
[29] R. Sutherland,et al. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] C. Sherr. Cancer Cell Cycles , 1996, Science.
[31] J. Pouysségur,et al. Cyclin D1 Expression Is Regulated Positively by the p42/p44MAPK and Negatively by the p38/HOGMAPK Pathway* , 1996, The Journal of Biological Chemistry.
[32] L. Altucci,et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.
[33] Holger Karas,et al. TRANSFAC: a database on transcription factors and their DNA binding sites , 1996, Nucleic Acids Res..
[34] K. Umesono,et al. The nuclear receptor superfamily: The second decade , 1995, Cell.
[35] Sutherland Rl,et al. Cell cycle control by steroid hormones. , 1994 .
[36] R. Sutherland,et al. Cell cycle control by steroid hormones. , 1994, Seminars in cancer biology.
[37] P Chambon,et al. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. , 1984, Nucleic acids research.
[38] W. McGuire,et al. Studies on the estrogen receptor in breast cancer. , 1973, Advances in experimental medicine and biology.